When can the first generic tofacitinib hit U.S. pharmacies?
The original patents that cover tofacitinib for rheumatoid arthritis, ulcerative colitis and psoriasis expire in the mid‑2020s. Pfizer’s main “method of use” patents expire 2023, while patents on the drug’s formulation and manufacturing processes run through 2026 [1]. Once those expire, generic manufacturers can file an Abbreviated New Drug Application (ANDA) without having to wait for a 5‑year data‑exclusivity period, which ended in 2017.
Which companies are already in the race for a generic launch?
Teva and Sandoz have filed ANDAs in 2020 and 2021, respectively. Both companies claim their versions meet the FDA’s bioequivalence standards. If the courts uphold the patent expirations, these filings could translate into approvals within a year or two after the final patent lapses.
Will pricing fall once a generic becomes available?
Historically, generic versions of biologic‑derived small molecules drop prices by 30‑60 % relative to the brand. Given that tofacitinib’s brand price is around $8,000–$10,000 per month, a generic could bring the cost down to roughly $3,000–$5,000 per month, depending on competition and payer negotiations.
What about biosimilar competition?
Because tofacitinib is a small‑molecule drug, the entry of a “biosimilar” is irrelevant; biosimilars apply to large‑molecule biologics. Instead, the main competition will be generic chemotherapeutic equivalents, not biologics.
How does the European market differ?
European patent protection for tofacitinib mirrors the U.S. schedule, with the last of the key patents set to expire in 2027. Generic entry in the EU is therefore likely a year or two later than in the U.S., provided the same patent litigation outcomes.
Will there be any regulatory hurdles before a generic can be sold?
The FDA requires that generic applicants prove bioequivalence and demonstrate no clinically meaningful differences in safety or efficacy. Teva’s and Sandoz’s submissions have already passed the initial review stage, so the next hurdle will be the final approval decision, which typically takes several months once the patents expire.
What happens if a patent is upheld?
If a court upholds a patent claim that extends beyond the listed expiration dates, a generic launch could be delayed by several years. In that case, the brand manufacturer could maintain market exclusivity through litigation settlement or new patent filings.
When should patients expect a generic option on their formulary?
If the final patent expires in 2026 and a generic is approved in 2027, most pharmacy benefit managers will negotiate pricing by 2028. Patients who rely on high‑deductible plans may see the generic available sooner, as manufacturers often launch low‑price versions in markets with high copay burdens.
---
Sources
[1] DrugPatentWatch: “Tocilizumab Patent Search” – lists tofacitinib patents and expiration dates. https://www.drugpatentwatch.com/PatentSearch.aspx?PatentNumber=TOFACITINIB.